mHealth-supported Coach

Sponsor
Food and Health Bureau, Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05422729
Collaborator
(none)
164
2
24

Study Details

Study Description

Brief Summary

A randomised controlled trial to evaluate the effects of a personalised mHealth-supported coach programme in the middle-aged group with stroke risk.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: mHealth-supported coaching
  • Behavioral: Conventional Health coaching
N/A

Detailed Description

Aim: To evaluate the effects of a personalised mHealth-supported coach programme on the adoption of health-promoting behaviours in the middle-aged group, in comparison with usual care.

Design: A 24-month prospective two-arm, parallel-group, single-blinded, repeated-measure randomised controlled trial will be conducted.

Participants: People who aged between 40 and 64, mentally competent, have a non-laboratory INTERHEART risk score (IHRS) of 10 or higher, communicable in Chinese and free from stroke and transient ischemic attack (TIA) or other cardiovascular disease will be eligible to the study. A total of 164 participants will be recruited through a district community centre and randomly assigned on 1:1 ratio to the intervention group or the control group.

Intervention: A theory-based mHealth-supported coach programme, including individual consultation sessions and a mobile application with a virtual sharing platform, is developed by a multidisciplinary team for the intervention group over three months, whereas the control group receives usual care.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
164 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Multidisciplinary-led Personalised mHealth-supported Coach for Reducing Midlife Stroke Risk
Anticipated Study Start Date :
Sep 5, 2022
Anticipated Primary Completion Date :
Jun 30, 2024
Anticipated Study Completion Date :
Sep 4, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Personalised mHeatlh-supported coaching programme

Three monthly individual consultation session, supported with a specific mobile application.

Behavioral: mHealth-supported coaching
The intervention includes two components. Three individual consultation sessions based on a health coaching protocol developed by a multidisciplinary team. A mobile application provides educational information about healthy lifestyles, knowledge quizzes, telemonitoring function and virtual platform for sharing.

Active Comparator: Traditional in-person health coaching programme

Three monthly individual consultation sessions.

Behavioral: Conventional Health coaching
Three individual consultation sessions delivered by a nurse.

Outcome Measures

Primary Outcome Measures

  1. Health-promoting behaviours [3-month post-allocation]

    Four subscales, including health responsibility, nutrition, physical activity and stress management, of the Health Promoting Lifestyle Profile II. The possible score range from 34 to 136, with a higher score meaning healthier lifestyles were adopted.

  2. Health-promoting behaviours [6-month post-allocation]

    Four subscales, including health responsibility, nutrition, physical activity and stress management, of the Health Promoting Lifestyle Profile II. The possible score range from 34 to 136, with a higher score meaning healthier lifestyles were adopted.

Secondary Outcome Measures

  1. Self-efficacy of adopting health-promoting behaviours [3-month post-allocation]

    The adapted version of the Diabetes Mellitus Type II Self Efficacy Scale will be used. Participants will rate their level of confidence in various behaviours, in diet control, weight control and lifestyle management, by using a five-point Likert scale. The possible scores ranged from 7 to 35, with a higher score meaning a higher level of self-efficacy.

  2. Self-efficacy [6-month post-allocation]

    The adapted version of the Diabetes Mellitus Type II Self Efficacy Scale will be used. Participants will rate their level of confidence in various behaviours, in diet control, weight control and lifestyle management, by using a five-point Likert scale. The possible scores ranged from 7 to 35, with a higher score meaning a higher level of self-efficacy.

  3. INTERHEART risk score [3-month post-allocation]

    The score was calculated based on the weighted sum of nine risk factors, including age, sex, lifestyles and psychosocial wellbeing, which were significantly related to cardiovasuclar diseases. The possible score range was 0 - 48, in which a higher score corresponds to higher risk.

  4. INTERHEART risk score [6-month post-allocation]

    The score was calculated based on the weighted sum of nine risk factors, including age, sex, lifestyles and psychosocial wellbeing, which were significantly related to cardiovasuclar diseases. The possible score range was 0 - 48, in which a higher score corresponds to higher risk.

  5. automatic retinal image analysis [3-month post-allocation]

    Retinal fundus image will be obtained from both eyes of the participant using a non-mydriatic digital retinal camera (Canon CR-2 AF, U.S.A., Inc). Stroke risk estimation will be determined through fractural analysis, statistical texture analysis and high-order spectra analysis based on the retinal vessel parameters. The ARIA-stroke algorithm developed using R and Matlab software has a sensitivity and a specificity of 94.7% and 100%, respectively. The value between 0.5 and 0.7 is considered as moderate risk, while high risk is considered at 0.7 or higher.

  6. automatic retinal image analysis (ARIA) [6-month post-allocation]

    Retinal fundus image will be obtained from both eyes of the participant using a non-mydriatic digital retinal camera (Canon CR-2 AF, U.S.A., Inc). Stroke risk estimation will be determined through fractural analysis, statistical texture analysis and high-order spectra analysis based on the retinal vessel parameters. The ARIA-stroke algorithm developed using R and Matlab software has a sensitivity and a specificity of 94.7% and 100%, respectively. The value between 0.5 and 0.7 is considered as moderate risk, while high risk is considered at 0.7 or higher.

  7. Psychological distress [3-month post-allocation]

    The Depression Anxiety Stress Scale (DASS-21)includes 21 items, with 7 in each subscale: depression, anxiety and stress. Participants will rate their level of agreement with the statements on a 4-point Likert scale, from 0 (not apply to me at all) to 3 (applied to me very much). The potential scores range from 0 to 63, with a higher score means higher level of distress experienced.

  8. Psychological distress [6-month post-allocation]

    The Depression Anxiety Stress Scale (DASS-21)includes 21 items, with 7 in each subscale: depression, anxiety and stress. Participants will rate their level of agreement with the statements on a 4-point Likert scale, from 0 (not apply to me at all) to 3 (applied to me very much). The potential scores range from 0 to 63, with a higher score means higher level of distress experienced.

  9. Change in Blood pressure [Between baseline and 3-month post-allocation]

    Blood pressure measurement will be carried out, after 10 min of rest, on the left arm in a sitting posture by using an electronic sphygmomanometer.

  10. Change in Blood pressure [Between 3-month and 6-month post-allocation]

    Blood pressure measurement will be carried out, after 10 min of rest, on the left arm in a sitting posture by using an electronic sphygmomanometer.

  11. Change in Body mass index (BMI) [Between baseline and 3-month post-allocation]

    BMI will be calculated by dividing the weight (in kilogram) by the height (in meter) squared. The height will be measured using a stadiometer, and body weight will be measured using an electronic scale.

  12. Change in Body mass index(BMI) [Between 3-month and 6-month post-allocation]

    BMI will be calculated by dividing the weight (in kilogram) by the height (in meter) squared. The height will be measured using a stadiometer, and body weight will be measured using an electronic scale.

  13. Change in Waist-hip ratio (WHR) [Between baseline and 3-month post-allocation]

    WHR will be used for determining body fat distribution. Waist circumference will be measured at the mid-point between the lowest rib and the iliac crest, whereas hip circumference will be measured at the widest level over the great trochanters. The two measurements will be measured to the nearest 0.1 cm by using a measuring tape.

  14. Change in Waist-hip ratio (WHR) [Between 3-month and 6-month post-allocation]

    WHR will be used for determining body fat distribution. Waist circumference will be measured at the mid-point between the lowest rib and the iliac crest, whereas hip circumference will be measured at the widest level over the great trochanters. The two measurements will be measured to the nearest 0.1 cm by using a measuring tape.

  15. Change in Fasting blood glucose [Between baseline and 3-month post-allocation]

    Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.

  16. Change in Fasting blood glucose [Between 3-month and 6-month post-allocation]

    Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.

  17. Change in Blood lipid profile [Between baseline and 3-month post-allocation]

    The profile includes ncluding triglyceride, total Cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C). Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.

  18. Change in Blood lipid profile [Between 3-month and 6-month post-allocation]

    The profile includes ncluding triglyceride, total Cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C). Blood samples will be taken by an experienced nurse and sent to accredited commercial biochemistry laboratories for analysis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Chinese ethnic

  • able to read Chinese and communicate in Cantonese/Mandarin

  • with non-laboratory IHRS score 10 or higher

Exclusion Criteria:
  • mentally incompetent

  • previously diagnosed with stroke, TIA, MI, coronary heart disease, heart failure or atrial fibrillation

  • with eye or retinal disease

  • with terminal disease with an expected life expectancy less than six months

  • being pregnant

  • have enrolled in other lifestyle-based or exercise-based projects

  • do have mobile devices or internet service to access the mobile application

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Food and Health Bureau, Hong Kong

Investigators

  • Principal Investigator: Helen Y Chan, Ph.D, Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Helen YL Chan, Associate Professor (Dr), Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05422729
Other Study ID Numbers:
  • 05200218
First Posted:
Jun 16, 2022
Last Update Posted:
Jun 16, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Helen YL Chan, Associate Professor (Dr), Chinese University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2022